Investors Compare Abbott Laboratories and Intuitive Surgical Amid Lingo Partnership
What happened
Investors are currently comparing established medical companies, such as Abbott Laboratories and Intuitive Surgical, against high-growth specialists like Lingo. Abbott Laboratories recently established an exclusive partnership with Berry Street to integrate Lingo’s glucose biowearable with dietitians for insurance-supported coaching. For the fiscal year 2025, Abbott Laboratories reported revenue of approximately $44.3 billion, showing 6% growth, and net income of around $6.5 billion.
From fool.com
Why it matters
The comparison highlights the difference between Abbott Laboratories’ diversified portfolio across nutrition, diagnostics, and devices, and Intuitive Surgical’s specialized focus on robotic-assisted surgery. This dynamic presents different risk and reward profiles for investors in the healthcare equipment market.
From fool.com
Who's involved
- Intuitive SurgicalA company specializing in robotic-assisted surgery.
- Abbott LaboratoriesA diversified global health care and medical device products company.
- LingoA technology providing glucose biowearable services integrated by Abbott Laboratories.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- LingoSpeculative
Lingo might gain new revenue streams and market validation through its strategic partnership with Abbott Laboratories.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Intuitive Surgical
American corporation
-
Abbott Laboratories
American global health care and medical device products company
- Corporate restructuring news includes the transformation of CORDIS from a division of Cardinal Health, the acquisitions of Guidant by Boston Scientific and Abbott Laboratories, and appointments involving Cirtec Medical.
- Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.
-
Lingo
scripting language